NEW YORK, Nov. 10, 2015 /PRNewswire/ -- The Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015 report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies.
The report provides a detailed understand and analysis of how and why companies enter licensing deals.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.
This report contains links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of licensing dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in licensing as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of licensing deals. The chapter includes numerous case studies to enable understanding of both pure licensing deals and multicomponent deals where licensing forms a part.
Chapter 4 provides a review of the leading licensing deals since 2011. Deals are listed by headline value, signed by bigpharma, most active big pharma, signed by big biotech, most active big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive review of licensing financials for deals announced since 2011, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials.
Chapters 6 and 7 provide a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of licensing deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 8 provides a comprehensive and detailed review of licensing deals signed and announced since 2011 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
The report also includes numerous table and figures that illustrate the trends and activities in licensing dealmaking since 2011.
In conclusion, this report provides everything a prospective dealmaker needs to know about licensing as an opportunity to participate in the commercialization of either candidate compounds in development or products already on the market.
In addition, a comprehensive appendix is provided organized by licensing company A-Z , stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about licensing partnering in the research, development and commercialization of technologies and products.
Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015 is intended to provide the reader with an in-depth understanding of the licensing trends and structure of deals entered into by leading life science companies worldwide.
Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015 includes:
Trends in licensing dealmaking in the biopharma industry since 2011
Analysis of licensing deal structure
Case studies of real-life licensing deals
Comprehensive listing of licensing deals since 2011
Access to licensing contract documents
Key financial bnchmarks for headline, upfront, milestone and royalty rates
The leading licensing deals by value since 2011
Most active licensing dealmakers since 2011
The leading licensing partnering resources
In Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015 available deals and contracts are listed by:
Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015 provides the reader with the following key benefits:
In-depth understanding of licensing partnering deal trends since 2011
Insight into the terms included in a licensing agreement, together with real world clause examples
Identify leading licensing deals by value since 2011
Identify the most active licensing dealmakers since 2011
Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
Full listing of licensing deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus
Comprehensive access to over 3,500 licensing deals entered into by the world's biopharma companies, together with contract documents if available
Detailed access to actual licensing contracts entered into by the leading fifty big pharma and big biotech companies
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Read the full report: http://www.reportlinker.com/p03375616-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.